PASG News and Press, Passage Bio Inc. From 08/12/25

2025-08-12 07:39:18 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...

Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Submit...

2025-07-10 08:05:56 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that it...

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy...

2025-05-13 07:53:27 ET More on Passage Bio Passage Bio GAAP EPS of -$1.07 misses by $0.12 Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seek...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high productivity, suspension-based manufacturing process for PBFT02 at American Society ...

2025-03-04 07:14:38 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...

Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 ...